Belén Gutiérrez-Gutiérrez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7021804/publications.pdf

Version: 2024-02-01

27 papers

1,522 citations

16 h-index 27 g-index

27 all docs

27 docs citations

27 times ranked

2152 citing authors

#	Article	IF	CITATIONS
1	Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clinical Microbiology Reviews, 2018, 31, .	13.6	486
2	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
3	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	3.0	89
4	Risks of Infection and Mortality Among Patients Colonized With Klebsiella pneumoniae Carbapenemase–Producing K. pneumoniae: Validation of Scores and Proposal for Management. Clinical Infectious Diseases, 2018, 66, 1204-1210.	5.8	81
5	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 783-792.	9.1	62
6	Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clinical Microbiology and Infection, 2022, 28, 550-557.	6.0	62
7	Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	59
8	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum \hat{I}^2 -Lactamase \hat{a} Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
9	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
10	Oral decontamination with aminoglycosides is associated with lower risk of mortality and infections in high-risk patients colonized with colistin-resistant, KPC-producing <i>Klebsiella pneumoniae</i> Journal of Antimicrobial Chemotherapy, 2016, 71, 3242-3249.	3.0	36
11	EUropean prospective cohort study on <i>Enterobacteriaceae</i> showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study. BMJ Open, 2017, 7, e015365.	1.9	22
12	Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0210721.	3.2	22
13	Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection. Journal of Clinical Medicine, 2021, 10, 2.	2.4	21
14	The use of predictive scores in the management of patients with carbapenem-resistant Klebsiella pneumoniae infection. Expert Review of Anti-Infective Therapy, 2019, 17, 265-273.	4.4	20
15	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. American Journal of Transplantation, 2020, 20, 1629-1641.	4.7	17
16	Outcome of community-onset ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bacteraemia and urinary tract infection: a population-based cohort study in Denmark. Journal of Antimicrobial Chemotherapy, 2020, 75, 3656-3664.	3.0	17
17	Predictive value of the kinetics of procalcitonin and C-reactive protein for early clinical stability in patients with bloodstream infections due to Gram-negative bacteria. Diagnostic Microbiology and Infectious Disease, 2019, 93, 63-68.	1.8	11
18	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. International Journal of Antimicrobial Agents, 2019, 54, 442-448.	2.5	11

#	Article	IF	CITATIONS
19	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Score–Adjusted Analysis. Open Forum Infectious Diseases, 2019, 6, ofz251.	0.9	11
20	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae $\hat{a} \in \text{``Authors''}$ reply. Lancet Infectious Diseases, The, 2017, 17, 1020-1021.	9.1	10
21	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
22	Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with <i>Clostridioides difficile</i> infection at high risk of recurrence: a matched cohort study. Journal of Antimicrobial Chemotherapy, 2022, 77, 1996-2002.	3.0	7
23	Extendedâ€spectrum βâ€lactamaseâ€producing and carbapenemâ€resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches. Transplant Infectious Disease, 2022, 24, .	1.7	5
24	Association between rectal colonisation by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae and mortality: a prospective, observational study. Journal of Global Antimicrobial Resistance, 2022, 29, 476-482.	2.2	4
25	Association between Timing of Colonization and Risk of Developing Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infection in Hospitalized Patients. Microbiology Spectrum, 2022, 10, e0197021.	3.0	4
26	Prognostic Significance of the Relative Load of KPC-Producing Klebsiella pneumoniae within the Intestinal Microbiota in a Prospective Cohort of Colonized Patients. Microbiology Spectrum, 2022, 10,	3.0	4
27	Ertapenem for treatment of non-severe bacteremic urinary-tract infections due to ESBL-producing Enterobacterales in kidney transplant recipients: a propensity score and DOOR-based analysis Antimicrobial Agents and Chemotherapy, 2021, 65, e0110221.	3.2	2